Who
Arthur T. Sands
President, CEO
Company insider
Files Form 4 as: President, CEO, Nurix Therapeutics; President & CEO, Lexicon Pharmaceuticals.
In numbers
- Trades disclosed
- 54
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $761K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Feb 2006
- Last trade
- 10 Feb 2026
- Last filed
- 10 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Feb 2026filed 10 Feb 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —562,500 at $0.00 | filing |
| 10 Feb 2026filed 10 Feb 2026 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —562,500 at $0.00 | filing |
| 11 Feb 2025filed 13 Feb 2025 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 14 Feb 2023filed 15 Feb 2023 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —448,000 at $0.00 | filing |
| 9 Aug 2022filed 10 Aug 2022 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 20 Jan 2022filed 21 Jan 2022 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 11 Feb 2021filed 12 Feb 2021 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 21 Oct 2020filed 23 Oct 2020 | NRIX Nurix Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —804,170 at $0.00 | filing |
| 28 Feb 2014filed 3 Mar 2014 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —36,250 | filing |
| 28 Feb 2014filed 3 Mar 2014 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —37,000 | filing |
| 28 Feb 2014filed 3 Mar 2014 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —35,000 | filing |
| 28 Feb 2014filed 3 Mar 2014 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $57K29,791 at $1.92 | filing |
| 28 Feb 2014filed 3 Mar 2014 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —36,250 | filing |
| 28 Feb 2014filed 3 Mar 2014 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,000 | filing |
| 28 Feb 2014filed 3 Mar 2014 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 | filing |
| 28 Feb 2013filed 1 Mar 2013 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —36,250 | filing |
| 28 Feb 2013filed 1 Mar 2013 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —37,000 | filing |
| 28 Feb 2013filed 1 Mar 2013 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $40K20,034 at $1.98 | filing |
| 28 Feb 2013filed 1 Mar 2013 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —36,250 | filing |
News
No headline names them, or the companies they trade most, lately.